Загрузка...
HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance
HER2 receptor tyrosine kinase that is overexpressed in approximately 20% of all breast cancers (BCs) is a poor prognosis factor and a precious target for BC therapy. Trastuzumab is approved by FDA to specifically target HER2 for treating HER2+ BC. However, about 60% of patients with HER2+ breast tum...
Сохранить в:
| Опубликовано в: : | Cancers (Basel) |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
MDPI
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5447950/ https://ncbi.nlm.nih.gov/pubmed/28445439 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers9050040 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|